Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia

Multiple Cancer Types

This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
Leukemia, Pediatric Leukemia
III
Friedman, Debra
NCT02101853
COGAALL1331

Yttrium Y 90 Resin Microspheres in Collecting Data from Patients with Liver Cancer That Cannot Be Removed by Surgery for the RESIN Liver Tumor Study

Liver

This research trial studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting SIR-spheres in non-resectable (RESIN) liver tumor study. The information generated will help doctors better understand treatment patterns involving Y90 therapy, gain additional insights in the long-term outcomes for patients, as well as guide future research for using Y90 therapy, especially for those conditions where data is currently very limited or lacking.
Liver
N/A
Brown, Daniel
NCT02685631
VICCGI1523

18F-FSPG PET / CT in Imaging Patients with Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

This phase II trial compares fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) / computed tomography (CT) to the standard of care fludeoxyglucose F-18 (18F-FDG) PET / CT in imaging patients with newly diagnosed lung cancer or indeterminate pulmonary nodules. PET / CT uses a radioactive glutamate (one of the common building blocks of protein) called 18F-FSPG which may be able to recognize differences between tumor and healthy tissue. Since tumor cells are growing, they need to make protein, and other building blocks, for cell growth that are made from glutamate and other molecules. PET / CT using a radioactive glutamate may be a more effective method of diagnosing lung cancer than the standard PET / CT using a radioactive glucose (sugar), such as 18F-FDG.
Not Available
II
Massion, Pierre
NCT02448225
VICCTHO1524

Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Multiple Cancer Types

This phase III ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient’s tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Lung, Non Small Cell
III
York, Sally
NCT02194738
ECOGTHOA151216

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Not Available
III
York, Sally
NCT02193282
ECOGTHOA081105

Characterization of Cardiac Function, Pulmonary Function, and Body Composition Before and After Concurrent Chemoradiotherapy for Head and Neck Cancer

Head/Neck

Head/Neck
N/A
Murphy, Barbara
VICCHN1533

AACR Project GENIE: Breast Cancer Sub-Project

Not Available
N/A
Park, Ben
VICCBRE1694

My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Miscellaneous

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
Miscellaneous
II
Davis, Elizabeth
NCT02091141
VICCMD16103

Research Use of Human Biospecimens from Glioblastoma Multiforme Patients

Neuro-Oncology

Neuro-Oncology
N/A
Thompson, Reid
VICCNEU16107

Prospective Observational Trial of an Absorbable Hydrogel Spacer in Prostate Cancer Radiotherapy

Prostate

Prostate
N/A
Kirschner, Austin
VICCURO16112

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: